13F Holdings
中文EN

MYGN MYRIAD GENETICS INC

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 899923 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.6%
TTM net income YoY67.8%
TTM EPS YoY69.0%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR—

Margins

Gross margin68.3%
Operating margin-14.3%
Net margin-16.1%
FCF margin—
EBITDA margin-10.0%

Returns

ROE-40.2%
ROA-19.3%
ROIC (approx.)-28.9%
Asset turnover1.20x

Leverage & solvency

Liabilities / assets55.8%
Debt / equity0.45x
Current ratio1.98x
Interest coverage-6.90x

Cash quality & payout

Operating cash flow / net income0.15x
Accruals ratio-16.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$824.50M$837.60M$753.20M$678.40M$690.60M
Cost of revenue$247.90M$252.20M$236.20M$202.00M—
Gross profit$576.60M$585.40M$517.00M$476.40M—
R&D expense$106.80M$113.40M$88.70M$85.40M$81.90M
SG&A expense$256.80M$275.90M$283.70M$247.90M$537.80M
Operating income-$387.20M-$123.50M-$257.40M-$140.60M-$190.50M
Interest expense$10.50M$2.80M$2.90M$3.20M$6.60M
Pretax income-$395.10M-$123.50M-$262.20M-$140.60M-$57.10M
Income tax-$29.20M$3.80M$1.10M-$28.60M-$29.90M
Net income-$365.90M-$127.30M-$263.30M-$112.00M-$27.20M
EBITDA-$333.50M-$62.30M-$195.50M-$87.90M-$127.70M
EPS (basic)-3.95-1.41-3.18-1.39-0.35
EPS (diluted)-3.95-1.41-3.18-1.39-0.35
Weighted avg. shares (diluted)92.60M90.60M82.80M80.60M78.00M
Balance sheet
Cash & equivalents$149.60M$111.90M$132.10M$66.40M$258.80M
Short-term investments—$0$8.80M$58.00M$81.40M
Receivables$115.30M$121.20M$114.30M$101.60M$91.30M
Inventory$30.60M$27.50M$22.00M$20.10M$15.30M
Current assets$332.60M$298.00M$313.60M$274.60M$484.80M
PP&E, net$114.00M$117.40M$119.00M$83.40M$43.50M
Goodwill$51.60M$286.30M$287.40M$286.80M$239.20M
Intangibles$153.40M$262.40M$349.50M$379.70M$404.10M
Total assets$706.60M$1.03B$1.15B$1.20B$1.32B
Current liabilities$133.80M$164.10M$155.90M$137.20M$204.30M
Short-term debt—$0———
Long-term debt$119.90M$39.60M$38.50M$0$0
Total debt$119.90M$39.60M$38.50M$0$0
Total liabilities$338.60M$326.50M$363.30M$312.90M$352.90M
Shareholders' equity$368.00M$701.10M$783.20M$885.80M$967.80M
Net debt-$29.70M-$72.30M-$93.60M-$66.40M-$258.80M
Shares outstanding93.50M91.30M89.90M81.20M80.00M
Cash flow statement
Operating cash flow$1.80M-$8.70M-$110.90M-$106.30M$18.60M
Capital expenditure———$45.30M$18.00M
Free cash flow———-$151.60M$600,000
Investing cash flow-$27.40M-$11.90M$31.90M-$77.50M$274.40M
Financing cash flow$64.20M-$7.40M$152.90M-$8.00M-$150.60M
Depreciation & amortization$53.70M$61.20M$61.90M$52.70M$62.80M
Stock-based compensation$35.20M$49.80M$40.70M$38.10M$36.30M
Share buybacks————$0

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.